Galectin Therapeutics
GALT
60 hedge funds and large institutions have $10.5M invested in Galectin Therapeutics in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 14 reducing their positions, and 3 closing their positions.
411% more call options, than puts
Call options by funds: $92K | Put options by funds: $18K
0.15% more ownership
Funds ownership: 12.07% → 12.22% (+0.15%)
0% more funds holding
Funds holding: 60 → 60 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
29% less capital invested
Capital invested by funds: $14.8M → $10.5M (-$4.35M)
43% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Osaic Holdings
Scottsdale,
Arizona
|
+$278K |
| 2 |
STA
Summit Trail Advisors
New York
|
+$33.9K |
| 3 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$27K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$12.2K |
| 5 |
Millennium Management
New York
|
+$11.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$85.1K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$35.2K |
| 3 |
State Street
Boston,
Massachusetts
|
-$20.9K |
| 4 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$13.7K |
| 5 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
-$9.75K |
GALT Hedge Fund Activity: Q2 2023 in Review
60 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q2 2023, worth a combined $10.5M — down 29% from $14.8M a quarter earlier.
Fund positioning in GALT was balanced in Q2 2023: 3 funds opened new positions, 3 closed out, 8 added to existing stakes and 14 trimmed.
The largest buyer was Osaic Holdings, adding an estimated $278K. The largest seller was Jane Street, exiting entirely with an estimated $85.1K sold.
- 60 institutional investors held Galectin Therapeutics (GALT) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $10.5M of Galectin Therapeutics stock for Q2 2023, down 29% quarter-over-quarter.
- 3 funds opened new Galectin Therapeutics positions in Q2 2023 and 3 closed out, a net change of 0 holders.
- The largest Galectin Therapeutics buyer in Q2 2023 was Osaic Holdings, an estimated $278K added.
- The largest Galectin Therapeutics seller in Q2 2023 was Jane Street, an estimated $85.1K sold.
Based on aggregated 13F filings for Q2 2023.